Company intelligence / Profile preview

Johnpro Biotech Inc.

Taipei, Taipei City, Taiwanprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Johnpro Biotech developed JP001 (Siroquine), a dual autophagy modulator targeting glioblastoma multiforme. The compound was licensed to HebaBiz Biotech, which has advanced it to phase II/III clinical trials in the US and Taiwan. Some safety and efficacy data have been obtained from patients; the drug is positioned as an innovative approach to overcoming chemoradiotherapy resistance in GBM by modulating autophagy and improving the tumor microenvironment[6][9].

Therapeutic areas: OtherOncology
Modalities: Small moleculesMolecular gluesChemical drugs[2]
Industry: Biotech

Drug pipeline

1 asset

siroquine

Phase 2/3

Indications: Glioblastoma

Partnerships

HebaBiz Biotech (exclusive global license for anti-tumor indications of JP001/Siroquine)[3][6]

Beyond the preview

Go deeper on Johnpro Biotech Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Johnpro Biotech Inc..

Explore the full profile